Short course of blinatumomab

Phase 2Monoclonal antibody

HHospital Universitario Dr. Jose E. Gonzalez

Short course of blinatumomab is one of 13 small molecule programs targeting Blinatumomab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BlinatumomabRecruiting

BlinatumomabPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Blinatumomab

#DrugCompanyPhaseTrials

Blincyto

Amgen

Phase 2

17 2

Venclexta

AbbVie

Phase 2

1 3

Trexall

Jazz Pharmaceuticals

Phase 2

1 4

Cytosar

Teva

Phase 2

1 5

Oncaspar

SServier

Phase 2

1 6

Decadron

AAspen Global Incorporated

Phase 2

1 7

Besponsa

WWyeth-Lederle Vaccines

Phase 2

1 8

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

1 9

Rayos

RRoxane Laboratories

Phase 1

1 10

Revuforj

SSyndax Pharmaceuticals

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Blinatumomab

NCT06886074

Clinical

Trials by Indication[1]

Blinatumomab1 trial

Efficacy of Short-course Blinatumomab for MRD Erradication in B-ALL

Recruiting·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT06886074·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Short course of blinatumomab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Short course of blinatumomab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Short course of blinatumomab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hospital Universitario Dr. Jose E. Gonzalez company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: HHospital Universitario Dr. Jose E. Gonzalez

Short course of blinatumomab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Blinatumomab1 trial

References

Drug Info

Quick Facts

Related News